No Data
No Data
BofA Securities Maintains BioXcel Therapeutics(BTAI.US) With Sell Rating
Bank of America Securities Remains a Sell on Bioxcel Therapeutics (BTAI)
BioXcel Therapeutics Advances Clinical Trials Amid Financial Adjustments
BioXcel Therapeutics | 10-Q: Q1 2025 Earnings Report
BioXcel Therapeutics Q1 EPS $(1.50) Beats $(4.16) Estimate, Sales $168.00K Miss $426.67K Estimate
BioXcel Therapeutics | 8-K: BioXcel Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update
71735916 : so bankruptcy within 2 quarters